Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025 16:41 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
September 18, 2025 21:26 ET | Source: Reviva Pharmaceuticals CUPERTINO, Calif., Sept.…
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
September 18, 2025 16:30 ET | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif.,…
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc.…
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2025 17:00 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept.…
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
August 28, 2025 19:30 ET | Source: Eagle Pharmaceuticals, Inc. WOODCLIFF LAKE,…
Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (Semnur), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.0
PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company…
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc.…
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq ListingRule 5635(c)(4)
August 15, 2025 16:05 ET | Source: X4 Pharmaceuticals BOSTON, Aug. 15,…
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
